4-Anilinoquinazoline-based benzenesulfonamides as nanomolar inhibitors of carbonic anhydrase isoforms I, II, IX, and XII: design, synthesis, in-vitro, and in-silico biological studies

References

• Supuran CT, Scozzafava A. Carbonic anhydrases as targets for medicinal chemistry. Bioorg Med Chem 2007;15:4336–50.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Carbonic anhydrases: novel therapeutic applications for inhibitors and activators. Nat Rev Drug Discov 2008;7:168–81.
   PubMed Web of Science ®Google Scholar
• Topal F, Aksu K, Gulcin I, et al. Inhibition profiles of some symmetric sulfamides derived from phenethylamines on human carbonic anhydrase I, and II isoenzymes. Chem Biodivers 2021;18:e2100422.
   PubMed Web of Science ®Google Scholar
• Durdagi S, Şentürk M, Ekinci D, et al. Kinetic and docking studies of phenol-based inhibitors of carbonic anhydrase isoforms I, II, IX and XII evidence a new binding mode within the enzyme active site. Bioorg Med Chem 2011;19:1381–9.
   PubMed Web of Science ®Google Scholar
• Nocentini A, Donald WA, Supuran CT. Chapter 8 – human carbonic anhydrases: tissue distribution, physiological role, and druggability. In: Supuran CT, Nocentini A, eds. Carbonic anhydrases. Cambridge: Academic Press; 2019:151–185.
   Google Scholar
• Quade BN, Parker MD, Occhipinti R. The therapeutic importance of acid-base balance. Biochem Pharmacol 2021;183:114278.
   PubMed Web of Science ®Google Scholar
• Supuran CT, Scozzafava A. Carbonic anhydrase inhibitors and their therapeutic potential. Expert Opin Ther Pat 2000;10:575–600.
   Web of Science ®Google Scholar
• Mohamed MM, Sloane BF. Cysteine cathepsins: multifunctional enzymes in cancer. Nat Rev Cancer 2006;6:764–75.
   PubMed Web of Science ®Google Scholar
• Annan DA, Maishi N, Soga T, et al. Carbonic anhydrase 2 (CAII) supports tumor blood endothelial cell survival under lactic acidosis in the tumor microenvironment. Cell Commun Signal 2019;17:169
   PubMed Web of Science ®Google Scholar
• Cuffaro D, Nuti E, Rossello A. An overview of carbohydrate-based carbonic anhydrase inhibitors. J Enzyme Inhib Med Chem 2020;35:1906–22.
   PubMed Web of Science ®Google Scholar
• Awadallah FM, Bua S, Mahmoud WR, et al. Inhibition studies on a panel of human carbonic anhydrases with N1-substituted secondary sulfonamides incorporating thiazolinone or imidazolone-indole tails. J Enzyme Inhib Med Chem 2018;33:629–38.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Experimental carbonic anhydrase inhibitors for the treatment of hypoxic tumors. J Exp Pharmacol 2020;12:603–17.
   PubMedGoogle Scholar
• Sanku RKk. Development and biological evaluation of carbonic anhydrase modulators as potential nootropics and anticancer agents. Ann Arbor: Temple University; 2018, pp. 154.
   Google Scholar
• Supuran CT. Advances in structure-based drug discovery of carbonic anhydrase inhibitors. Expert Opin Drug Discov 2017;12:61–88.
   PubMed Web of Science ®Google Scholar
• Supuran CT. Exploring the multiple binding modes of inhibitors to carbonic anhydrases for novel drug discovery. Expert Opin Drug Discov 2020;15:671–86.
   PubMed Web of Science ®Google Scholar
• Aggarwal M, Kondeti B, McKenna R. Insights towards sulfonamide drug specificity in α-carbonic anhydrases. Bioorg Med Chem 2013;21:1526–33.
   PubMed Web of Science ®Google Scholar
• Carta F, Supuran CT, Scozzafava A. Sulfonamides and their isosters as carbonic anhydrase inhibitors. Future Med Chem 2014;6:1149–65.
   PubMed Web of Science ®Google Scholar
• McDonald PC, Chia S, Bedard PL, et al. A phase 1 study of SLC-0111, a novel inhibitor of carbonic anhydrase IX, in patients with advanced solid tumors. Am J Clin Oncol 2020;43:484–90.
   PubMed Web of Science ®Google Scholar
• Hampson AJ, Babalonis S, Lofwall MR, et al. A pharmacokinetic study examining acetazolamide as a novel adherence marker for clinical trials. J Clin Psychopharmacol 2016;36:324–32.
   PubMed Web of Science ®Google Scholar
• Yuan L, Wang M, Liu T, et al. Carbonic anhydrase 1-mediated calcification is associated with atherosclerosis, and methazolamide alleviates its pathogenesis. Front Pharmacol, 2019;10:766.
   PubMed Web of Science ®Google Scholar
• Yu-Jing YJ, Zhang CM, Liu ZP. Recent developments of small molecule EGFR inhibitors based on the quinazoline core scaffolds. Anticancer Agents Med Chem 2012;12:391–406.
   PubMed Web of Science ®Google Scholar
• Elkamhawy A, Farag AK, Viswanath AN, et al. Targeting EGFR/HER2 tyrosine kinases with a new potent series of 6-substituted 4-anilinoquinazoline hybrids: design, synthesis, kinase assay, cell-based assay, and molecular docking. Bioorg Med Chem Lett 2015;25:5147–54.
   PubMed Web of Science ®Google Scholar
• Cohen MH, Williams GA, Sridhara R, et al. FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets. The Oncologist 2003;8:303–6.
   PubMed Web of Science ®Google Scholar
• Johnson JR, Cohen M, Sridhara R, et al. Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen. Clin Cancer Res 2005;11:6414–21.
   PubMed Web of Science ®Google Scholar
• Cortazar P, Justice R, Johnson J, et al. US Food and Drug Administration approval overview in metastatic breast cancer. J Clin Oncol 2012;30:1705–11.
   PubMed Web of Science ®Google Scholar
• Zhang D, Pal A, Bornmann WG, et al. Activity of lapatinib is independent of EGFR expression level in HER2-overexpressing breast cancer cells. Mol Cancer Ther 2008;7:1846–50.
   PubMed Web of Science ®Google Scholar
• Degrauwe N, Sosa JA, Roman S, Deshpande HA. Vandetanib for the treatment of metastatic medullary thyroid cancer. Clin Med Insights Oncol 2012;6:CMO.S7999.
   Google Scholar
• Tan F, Shi Y, Wang Y, et al. Icotinib, a selective EGF receptor tyrosine kinase inhibitor, for the treatment of non-small-cell lung cancer. Future Oncol 2015;11:385–97.
   PubMed Web of Science ®Google Scholar
• Yu HA, Pao W. Targeted therapies: Afatinib-new therapy option for EGFR-mutant lung cancer. Nature Rev Clin Oncol 2013;10:551–2.
   PubMed Web of Science ®Google Scholar
• Asif M. Chemical characteristics, synthetic methods, and biological potential of quinazoline and quinazolinone derivatives. Int J Med Chem 2014;2014:395637.
   PubMedGoogle Scholar
• Elkamhawy A, Viswanath AN, Pae AN, et al. Discovery of potent and selective cytotoxic activity of new quinazoline-ureas against TMZ-resistant glioblastoma multiforme (GBM). Eur J Med Chem 2015;103:210–22.
   PubMed Web of Science ®Google Scholar
• Alafeefy AM, Ceruso M, Al-Tamimi A-MS, et al. Quinazoline-sulfonamides with potent inhibitory activity against the α-carbonic anhydrase from Vibrio cholerae. Bioorg Med Chem 2014;22:5133–40.
   PubMed Web of Science ®Google Scholar
• Alafeefy AM, Ceruso M, Al-Jaber NA, et al. A new class of quinazoline-sulfonamides acting as efficient inhibitors against the α-carbonic anhydrase from Trypanosoma cruzi. J Enzyme Inhib Med Chem 2015;30:581–5.
   PubMed Web of Science ®Google Scholar
• Lee K, Nada H, Byun HJ, et al. Hit identification of a Novel quinazoline sulfonamide as a promising EphB3 inhibitor: design, virtual combinatorial library, synthesis, biological evaluation, and docking simulation studies. Pharmaceuticals. 2021;14:1247.
   Web of Science ®Google Scholar
• Maresca A, Temperini C, Vu H, et al. Non-zinc mediated inhibition of carbonic anhydrases: coumarins are a new class of suicide inhibitors. J Am Chem Soc 2009;131:3057–62.
   PubMed Web of Science ®Google Scholar
• Menchise V, De Simone G, Alterio V, et al. Carbonic anhydrase inhibitors: stacking with Phe131 determines active site binding region of inhibitors as exemplified by the X-ray crystal structure of a membrane-impermeant antitumor sulfonamide complexed with isozyme II. J Med Chem 2005;48:5721–7.
   PubMed Web of Science ®Google Scholar
• Margheri F, Ceruso M, Carta F, et al. Overexpression of the transmembrane carbonic anhydrase isoforms IX and XII in the inflamed synovium. J Enzyme Inhib Med Chem 2016;31:60–3.
   PubMed Web of Science ®Google Scholar
• Bozdag M, Ferraroni M, Nuti E, et al. Combining the tail and the ring approaches for obtaining potent and isoform-selective carbonic anhydrase inhibitors: solution and X-ray crystallographic studies. Bioorg Med Chem 2014;22:334–40.
   PubMed Web of Science ®Google Scholar
• Ali M, Bozdag M, Farooq U, et al. Benzylaminoethyureido-tailed benzenesulfonamides: design, synthesis, kinetic and X-ray investigations on human carbonic anhydrases. Int J Mol Sci. 2020;21:2560.
   PubMed Web of Science ®Google Scholar
• Leitans J, Sprudza A, Tanc M, et al. 5-Substituted-(1,2,3-triazol-4-yl)thiophene-2-sulfonamides strongly inhibit human carbonic anhydrases I, II, IX and XII: solution and X-ray crystallographic studies. Bioorg Med Chem 2013;21:5130–8.
   PubMed Web of Science ®Google Scholar
• Buemi MR, De Luca L, Ferro S, et al. Carbonic anhydrase inhibitors: design, synthesis and structural characterization of new heteroaryl-N-carbonylbenzenesulfonamides targeting druggable human carbonic anhydrase isoforms. Eur J Med Chem 2015;102:223–32.
   PubMed Web of Science ®Google Scholar
• Whittington DA, Waheed A, Ulmasov B, et al. Crystal structure of the dimeric extracellular domain of human carbonic anhydrase XII, a bitopic membrane protein overexpressed in certain cancer tumor cells. Proc Natl Acad Sci USA. 2001;98:9545–50.
   PubMed Web of Science ®Google Scholar
• Elkamhawy A, Kim NY, Hassan AHE, et al. Design, synthesis and biological evaluation of novel thiazolidinedione derivatives as irreversible allosteric IKK-β modulators. Eur J Med Chem 2018;157:691–704.
   PubMed Web of Science ®Google Scholar
• Park JE, Elkamhawy A, Hassan AHE, et al. Synthesis and evaluation of new pyridyl/pyrazinyl thiourea derivatives: neuroprotection against amyloid-β-induced toxicity. Eur J Med Chem 2017;141:322–34.
   PubMed Web of Science ®Google Scholar
• Al-Sanea MM, Elkamhawy A, Zakaria A, et al. Synthesis and in vitro screening of phenylbipyridinylpyrazole derivatives as potential antiproliferative agents. Molecules 2015;20:1031–45.
   PubMedGoogle Scholar
• Macalino SJY, Gosu V, Hong S, Choi S. Role of computer-aided drug design in modern drug discovery. Arch Pharm Res 2015;38:1686–701.
   PubMed Web of Science ®Google Scholar
• Guedes IA, de Magalhães CS, Dardenne LEJBr. Receptor-ligand molecular docking. Biophys Rev. 2014;6:75–87.
   PubMedGoogle Scholar
• Wang J, Li Y, Yang Y, et al. In silico research to assist the investigation of carboxamide derivatives as potent TRPV1 antagonists. Mol BioSystems 2015;11:2885–99.
   PubMedGoogle Scholar
• Shaldam M, Nocentini A, Elsayed ZM, et al. Development of novel Quinoline-based sulfonamides as selective cancer-associated carbonic anhydrase isoform IX inhibitors. Int J Mol Sci 2021;22:11119.
   PubMed Web of Science ®Google Scholar